Views & Analysis ‘No going back’ for clinical trials after COVID Trial sites have adapted swiftly to the restrictions of COVID-19, and patients have seen many knock-on benefits as a result.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
